Properties
What is it?
International Nonproprietary Name - Argininum Pharmacological Group: Parenteral agents for rehydration and detoxification Composition: L-arginine hydrochloride; 1 ml of solution contains 42 mg of arginine hydrochloride (100 ml contains 20 mmol of arginine and 10 mmol of chloride); Excipients: Water for injection. Dosage Form. Solution for infusion. Main Physicochemical Properties: Clear, colorless or slightly yellowish-brown solution; pH 5.0-6.5. Theoretical osmolarity 398 mOsmol/l. Pharmacotherapeutic Group. Blood substitutes and perfusion solutions. Additional solutions for intravenous administration. Amino acids. Arginine hydrochloride. ATC Code B05XB01. Clinical Characteristics. Indications. Metabolic alkalosis, hyperammonemia, atherosclerosis of the coronary and cerebral arteries, atherosclerosis of peripheral arteries, including with manifestations of intermittent claudication, diabetic angiopathy, arterial hypertension, chronic heart failure, hypercholesterolemia, chronic obstructive pulmonary diseases, pulmonary hypertension, fetal growth retardation and preeclampsia - as part of complex therapy. Contraindications. Hypersensitivity to the drug. Severe renal impairment, hyperchloremic acidosis; allergic reactions in history; use of potassium-sparing diuretics, as well as spironolactone. Myocardial infarction (including in history). Interactions with other medicinal products and other types of interactions. When using Tivortin®, it should be taken into account that the drug can cause pronounced and persistent hyperkalemia in patients with renal insufficiency who are taking or have taken spironolactone. Prior use of potassium-sparing diuretics can also contribute to an increase in blood potassium concentration. Concomitant use with aminophylline may increase insulin levels in the blood. Arginine is incompatible with thiopental. Method of administration and dosage. The drug is administered intravenously by drip at a rate of 10 drops per minute for the first 10-15 minutes, then the infusion rate can be increased to 30 drops per minute. The daily dose of the drug is 100 ml of solution. In severe disorders of central and peripheral blood circulation, intoxication, pronounced manifestations of hypoxia, asthenic conditions, the dose of the drug can be increased to 200 ml per day. The maximum infusion rate of the solution for infusion should not exceed 20 mmol/hour. In children under 12 years of age, the dose of the drug is 5-10 ml per 1 kg of body weight per day. To treat metabolic alkalosis, the dose can be calculated as follows: Arginine hydrochloride (mmol) X 0.3 X kg of body weight Excess base (BE) (mmol/l) Administration should be started with half of the calculated dose. Possible further correction should be carried out after obtaining the results of the updated acid-base balance. Children. The drug is used in children from 3 years of age. Use during pregnancy or breastfeeding. The drug crosses the placenta, so its use during pregnancy is possible only when the expected benefit to the mother outweighs the potential risk to the fetus. There is no data on the use of the drug during breastfeeding. Ability to affect reaction rate when driving vehicles or operating machinery. When driving vehicles or operating machinery, caution should be exercised, as the drug can cause dizziness.